Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| CELG | Celgene Corporation | -1.94% | 88.65 | 1.3% | $803.98m | |
| AMGN | Amgen Inc. | -0.76% | 185.50 | 1.2% | $628.99m | |
| GILD | Gilead Sciences, Inc. | -2.14% | 65.55 | 0.9% | $482.29m | |
| BIIB | Biogen Inc. | -4.17% | 321.17 | 1.3% | $427.44m | |
| ILMN | Illumina, Inc. | -1.77% | 296.88 | 3.5% | $311.35m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.92% | 418.62 | 2.6% | $290.18m | |
| VRTX | Vertex Pharmaceuticals Incorporated | -2.55% | 183.06 | 1.9% | $253.58m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -1.76% | 127.55 | 2.0% | $219.68m | |
| SRPT | Sarepta Therapeutics, Inc. | -2.87% | 136.54 | 15.4% | $152.33m | |
| A | Agilent Technologies, Inc. | -0.83% | 77.91 | 1.6% | $150.84m | |
| EXAS | Exact Sciences Corporation | -0.42% | 83.28 | 25.3% | $132.28m | |
| INCY | Incyte Corporation | -0.49% | 83.33 | 2.5% | $111.93m | |
| ARRY | Array BioPharma Inc. | -1.99% | 22.71 | 8.2% | $108.01m | |
| EXEL | Exelixis, Inc. | -0.09% | 21.22 | 6.4% | $82.07m | |
| NBIX | Neurocrine Biosciences, Inc. | -2.58% | 77.31 | 5.1% | $77.22m |
Company Profile
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. It focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Its current product development programs include Fostamatinib Oral SYK Inhibitor and R348 Topical Ophthalmic JAK/SYK Inhibitor. The company was founded by Donald G. Payan, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.